SUMO通路相关预后模型： 从跨癌证据到胰腺导管腺癌的分层与免疫治疗策略

海 永平1, 王海 久*2
1、青海大学临床医学院
2、青海大学附属医院普通外科

摘要


小泛素样修饰物（SUMO）通路通过调控染色质稳定性、DNA修复、细胞周期及免疫信号，在多种肿瘤
的发生发展中发挥核心作用，其在胰腺导管腺癌（PDAC）中的异常激活尤为显著。近年来，基于SUMO相关基
因的预后模型在多癌种中不断涌现，为理解肿瘤异质性及开展风险分层提供了新的思路。本文系统整合跨癌种证
据，梳理SUMO通路在肿瘤生物学、免疫调控与治疗响应中的关键环节，并总结已报道的SUMO相关预后模型
的构建策略与验证特点。结合现有PDAC研究，我们进一步讨论了SUMO通路在PDAC亚型识别、免疫微环境重
塑及靶向治疗（如TAK-981）中的潜在应用价值。综述认为，SUMO通路在预后评估、机制研究及免疫治疗策
略开发方面均具有重要转化潜力，但模型的外部验证、一致化构建流程及机制深度仍需进一步加强，以推动其在
PDAC中的规范化应用。

关键词


SUMO通路；预后模型；胰腺导管腺癌；免疫微环境；TAK-981

全文:

PDF


参考


[1]Schneeweis C, Hassan Z, Schick M, Keller U,

Schneider G. The SUMO pathway in pancreatic cancer:

insights and inhibition. *British Journal of Cancer*.

2021;124(3):531-538.

[2]Duan Y, Du Y, Mu Y, Gu Z, Wang C. Prognostic

value, immune signature and molecular mechanisms of the

SUMO family in pancreatic adenocarcinoma. *Frontiers in

Molecular Biosciences*. 2022;9:1096679.

[3]Gu Y, Fang Y, Wu X, Xu T, Hu T, Xu Y,

et al. The emerging roles of SUMOylation in the

tumor microenvironment and therapeutic implications.

*Experimental Hematology & Oncology*. 2023;12(1):58.

[4]Chen Y. A new immuno-oncology target -

SUMOylation. *Trends in Cancer*. 2023;9(8):606-608.

[5]Peng W, Yang Z, Yan R, Mu L, Li L, Jin S, et al.

SUMOylation-regulated genes in colon cancer: expression

patterns and clinical implications. *Discover Oncology*.

2025;16(1):837.

[6]Chen Z, Yang J, Tang L, Sun X, Li Y, Sheng Z,

et al. SUMOylation patterns and signature characterize the

tumor microenvironment and predict prognosis in lung

adenocarcinoma. *Frontiers in Cell and Developmental

Biology*. 2023;11:1094588.

[7]Wang J, Cong P, Jin Z, Liu L, Sun D, Zhu W, et

al. A novel prognostic signature for hepatocellular carcinoma

based on SUMOylation-related genes. *Scientific Reports*.

2023;13(1):11233.

[8]Wu X, Li J-H, Xu L, Li Y-X, Zhu X-X, Wang

X-Y, et al. SUMO specific peptidase 3 halts pancreatic ductal

adenocarcinoma metastasis via deSUMOylating DKC1. *Cell

Death & Differentiation*. 2023;30(7):1742-1756.

[9]Biederstädt A, Hassan Z, Schneeweis C, Schick

M, Schneider L, Muckenhuber A, et al. SUMO pathway

inhibition targets an aggressive pancreatic cancer subtype.

*Gut*. 2020;69(8):1472-1482.

[10]Wang X, Yang C, Liu Y, Wang J. SUMOylation

substrate encoding genes as prognostic biomarkers in

pancreatic ductal adenocarcinoma with functional assessment

of SAF-B2. *Frontiers in Pharmacology*. 2025;16:1532658.

[11]Langston SP, Grossman S, England D, Afroze R,

Bence N, Bowman D, et al. Discovery of TAK-981, a

first-in-class inhibitor of SUMO-activating enzyme for

the treatment of cancer. *Journal of Medicinal Chemistry*.

2021;64(5):2501-2520.

[12]Kumar S, Schoonderwoerd MJA, Kroonen JS, de

Graaf IJ, Sluijter M, Ruano D, et al. Targeting pancreatic

cancer by TAK-981: a SUMOylation inhibitor that activates

the immune system and blocks cancer cell cycle progression in

a preclinical model. *Gut*. 2022;71(11):2266-2283.

[13]Erdem S, Lee HJ, Shankara Narayanan JSN,

Tharuka MDN, de la Torre J, Ren T, et al. Inhibition of

SUMOylation induces adaptive antitumor immunity against

pancreatic cancer through multiple effects on the tumor

microenvironment. *Molecular Cancer Therapeutics*.

2024;23(11):1597-1612.

[14]de la Torre Medina J, Joshi U, Sonowal H, Kuang Y,

Ren T, Chen D-H, et al. Immunomodulation of pancreatic

cancer via inhibition of SUMOylation and CD155/TIGIT

pathway. *bioRxiv*. 2025:2025.02.06.636475.

[15]Qian Y, Daza J, Itzel T, Betge J, Zhan T, Marmé

F, et al. Prognostic cancer gene expression signatures: current

status and challenges. Cells. 2021;10(3):648.


Refbacks

  • 当前没有refback。